{"transactions":[{"id":676260,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Incentive Share Option","published_at":"2026-08-26T01:55:36.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Not applicable - the reported transaction is the exercise of the stock option for the exercise price set forth in Column 2; no separate consideration was paid or received for the derivative security."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised."}],"balance_after":390796,"derivative":{"exercise_price":0.815,"exercise_date":"2024-10-31","expiration_date":"2034-10-29","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-093698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390026093698/ownership.xml","form_type":"4"}},{"id":676259,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-08-26T01:55:36.000Z","date":"2026-08-18","kind":"exercise","planned":false,"acquired":true,"shares":100000,"price":0.815,"value":81500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the 265,488 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise."}],"balance_after":365488,"source":{"system":"sec-edgar","filing":"0001213900-26-093698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390026093698/ownership.xml","form_type":"4"}},{"id":798053,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-04-30T01:36:42.000Z","date":"2025-10-07","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":1.33,"value":1330.0,"ownership":{"direct":true},"balance_after":265488,"source":{"system":"sec-edgar","filing":"0001213900-26-049602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390026049602/ownership.xml","form_type":"4"}},{"id":798052,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-04-30T01:36:42.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":1.16,"value":1160.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":16700,"source":{"system":"sec-edgar","filing":"0001213900-26-049602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390026049602/ownership.xml","form_type":"4"}},{"id":798051,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2026-04-30T01:36:42.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":1.04,"value":104.0,"ownership":{"direct":true},"balance_after":264588,"source":{"system":"sec-edgar","filing":"0001213900-26-049602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390026049602/ownership.xml","form_type":"4"}},{"id":1267670,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Nonstatutory Share Option","published_at":"2025-02-14T21:30:12.000Z","date":"2024-10-30","kind":"grant","planned":false,"acquired":true,"shares":509204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months. Each subsequent monthly vesting will represent a total of 1/48 of the total award, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months. Each subsequent monthly vesting will represent a total of 1/48 of the total award, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024."}],"balance_after":509203,"derivative":{"exercise_price":0.815,"exercise_date":"2024-10-31","expiration_date":"2034-10-29","underlying":"Common Stock","underlying_shares":509204},"source":{"system":"sec-edgar","filing":"0001213900-25-014306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390025014306/ownership.xml","form_type":"4"}},{"id":1267669,"issuer":{"id":7442,"kind":"organization","name":"Estrella Immunopharma, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Incentive Share Option","published_at":"2025-02-14T21:30:12.000Z","date":"2024-10-30","kind":"grant","planned":false,"acquired":true,"shares":490796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 30, 2024, the Board of Directors (the \"Board\") of Estrella Immunopharma, Inc. (the \"Company\"), awarded Mr. Jiangdong \"Peter\" Xu an incentive share option grant of 490,796 shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 30, 2024, the Board of Directors (the \"Board\") of Estrella Immunopharma, Inc. (the \"Company\"), awarded Mr. Jiangdong \"Peter\" Xu an incentive share option grant of 490,796 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 31, 2024, the Board of the Company awarded Mr. Xu a nonstatutory shares option grant of 509,204 shares."}],"balance_after":490796,"derivative":{"exercise_price":0.815,"exercise_date":"2024-10-31","expiration_date":"2034-10-29","underlying":"Common Stock","underlying_shares":490796},"source":{"system":"sec-edgar","filing":"0001213900-25-014306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390025014306/ownership.xml","form_type":"4"}},{"id":1406802,"issuer":{"id":6623,"kind":"organization","name":"Semnur Pharmaceuticals, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2024-09-16T14:01:42.000Z","date":"2024-08-30","kind":"sale","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Ordinary Shares\"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. (\"Semnur\"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company (\"Scilex\") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the \"SIPA\"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the \"Cash Consideration\") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the \"Scilex Shares\"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. (\"Semnur\"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company (\"Scilex\") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the \"SIPA\"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the \"Cash Consideration\") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the \"Scilex Shares\"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Ordinary Shares\"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Ordinary Shares\"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly."}],"balance_after":1432500,"derivative":{"underlying":"Class B Ordinary Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-24-078774","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000121390024078774/ownership.xml","form_type":"4"}},{"id":2258632,"issuer":{"id":6623,"kind":"organization","name":"Semnur Pharmaceuticals, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2022-05-24T20:20:50.000Z","date":"2022-05-21","kind":"disposition_to_issuer","acquired":false,"shares":93750,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by Denali Capital Global Investments LLC (the \"Sponsor\"), depending on the extent to which the underwriters' over-allotment option is exercised.  The underwriters only partially exercised their over-allotment option, resulting in the Sponsor forfeiting 93,750 Class B ordinary shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described in the Reporting Person's Form 3 filed April 6, 2022, an aggregate of 281,250 Class B ordinary shares were subject to forfeiture to the Issuer for no consideration by Denali Capital Global Investments LLC (the \"Sponsor\"), depending on the extent to which the underwriters' over-allotment option is exercised.  The underwriters only partially exercised their over-allotment option, resulting in the Sponsor forfeiting 93,750 Class B ordinary shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination on a one-for-one basis, subject to adjustment, and have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Class B ordinary shares are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly."}],"balance_after":1932500,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001567619-22-011622","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000156761922011622/doc1.xml","form_type":"4"}},{"id":2297885,"issuer":{"id":6623,"kind":"organization","name":"Semnur Pharmaceuticals, Inc."},"owners":[{"id":19958,"kind":"person","name":"Xu Jiandong","position":1,"cik":"0001920399","reported_name":"Xu Jiandong","relationship":{"ten_percent_owner":true}}],"security":"Class A Ordinary Shares","published_at":"2022-04-13T20:51:17.000Z","date":"2022-04-11","kind":"purchase","acquired":true,"shares":510000,"price":10,"value":5100000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Class A Ordinary Shares underlying units (each unit having a price of $10.00 and consisting of one Class A Ordinary Share and one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A Ordinary Share at a price of $11.50 per share) that were acquired by Denali Capital Global Investments LLC (the \"Sponsor\") in a private placement effected concurrently with the closing of the Issuer's initial public offering, based on the partial exercise of the underwriters' over-allotment option."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These Class A Ordinary Shares underlying units are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares underlying units held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares underlying units held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Class A Ordinary Shares underlying units are held directly by the Sponsor. The Reporting Person is the manager and controlling member of the Sponsor and, as such, may be deemed to beneficially own the ordinary shares underlying units held directly by the Sponsor. The Reporting Person disclaims any beneficial ownership of the ordinary shares underlying units held directly by the Sponsor, other than to the extent of any pecuniary interest he may have therein, directly or indirectly."}],"balance_after":510000,"source":{"system":"sec-edgar","filing":"0001140361-22-014405","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920399/000114036122014405/form4.xml","form_type":"4"}}]}